SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors aggressively position ahead of its quarterly earnings release, with significant debate surrounding the stock's massive short interest and the potential for a short squeeze if management delivers strong guidance. Community discourse is heavily focused on the company's competitive standing in the AI infrastructure sector, with bulls highlighting strategic partnerships while bears continue to cite concerns over infrastructure bottlenecks and aggressive valuations.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending after reporting strong fiscal earnings and issuing aggressive forward revenue guidance that significantly outpaced analyst expectations, signaling robust demand for its AI infrastructure. Investors are actively debating the stock's potential for a short squeeze as community members emphasize the company's record backlog and management's decision to suspend planned share dilution despite ongoing skepticism regarding governance and competitive pressure.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is rallying following a strong earnings report that highlighted triple-digit revenue growth and a massive, expanding backlog that signals robust AI infrastructure demand. While the community is actively debating the company's heavy capital expenditures and debt load versus its potential as a critical AI compute provider, bullish sentiment is being fueled by a potential short squeeze as investors weigh the company's aggressive growth against broader sector trends.

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

Liquidia Corp

Liquidia Corp is experiencing heightened volatility and intense investor focus as the market awaits a pivotal court ruling regarding its patent litigation, which remains a key catalyst for the stock. The community is actively debating the impact of the ongoing legal battle versus the drug's strong commercial launch and potential market share expansion in the pulmonary hypertension space.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is currently drawing investor attention as it navigates a volatility-driven pullback, with many in the community viewing recent price action as a disconnect from improving fundamentals and the company's clear path toward profitability by 2027. Investors are actively discussing the long-term potential of the African e-commerce sector, with sentiment bolstered by strategic partnerships and a focus on operational efficiency, even as broader market instability and geopolitical concerns keep near-term sentiment cautious.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is experiencing significant market attention following positive topline Phase 3 results for its DT120 program, which met primary and secondary endpoints in treating major depressive disorder. The community is actively debating the stock's valuation and potential dilution risks after an upsized equity offering was announced alongside the trial success, with many long-term investors highlighting the drug's upcoming catalysts in generalized anxiety disorder as the next critical milestone.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is surging following strong Q2 earnings that surpassed expectations, highlighted by a significant revenue boost and a raised full-year guidance as demand for its metal 3D printing technology accelerates in the defense and aerospace sectors. Community sentiment remains aggressively bullish, with investors actively discussing potential short squeezes and a massive growth phase fueled by the company's manufacturing capacity expansion.

T1 Energy, Inc. engages in providing energy solutions focused on solar module and solar cell manufacturing. It focuses on building an integrated U.S. supply chain for solar and batteries. The company was founded by Tom Einar Jensen, Peter Matrai, and Tore Ivar Slettemoen on August 31, 2023 and is headquartered in Austin, TX.

T1 Energy Inc.

T1 Energy is experiencing heightened volatility and intense social media discussion as investors debate the impact of preliminary earnings, project delays at its G2 Austin facility, and ongoing concerns regarding capital financing. Despite these headwinds, the community remains divided, with many long-term bulls viewing current price levels as a significant discount and pointing to rising energy demand for AI data centers as a key long-term catalyst.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates

Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of +3.13% and +67.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, July 27, 2026 NEW YORK, July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...

Is Kymera Therapeutics Poised for a Breakthrough With KT-621?

Kymera Therapeutics advances KT-621 enrollment ahead of schedule, bringing pivotal atopic dermatitis data closer as it expands its protein degrader pipeline.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) PR Newswire NEW YORK, July 16, 2026 NEW YORK, July...

KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug

KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.

Why Kymera Therapeutics Stock Popped This Week

Key PointsIt completed the enrollment phase of a Phase 2b study of its leading drug candidate...

Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study

KYMR stock soars 17% as investor optimism was lifted following early enrollment completion in mid-stage AD study, moving KT-621 top-line data to year-end 2026.

Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?

Kymera Therapeutics (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline

Equity

Kymera said that it finished enrolling patients nearly six months ahead of schedule in a mid-stage trial for KT-621.


$KYMR Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.62 up 34.74% YoY
• Reported revenue of $65M up 466.40% YoY

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.

Kymera Therapeutics Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

KYMRKymera Therapeutics Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest KYMR News